Pertactin-negative bordetella pertussis strains: Evidence for a possible selective advantage

Clinical Infectious Diseases

Volumn 60, Issue 2, 2015, Pages 223-227

  Martin, Stacey W ^a   Pawloski, Lucia ^a   Williams, Margaret ^a   Weening, Keeley ^b   Debolt, Chas ^c   Qin, Xuan ^d   Reynolds, Laura ^e   Kenyon, Cynthia ^f   Giambrone, Gregory ^g   Kudish, Kathy ^h   Miller, Lisa ⁱ   Selvage, David ^j   Lee, Adria ^a   Skoff, Tami H ^a   Kamiya, Hajime ^a   Cassiday, Pamela K ^a   Tondella, Maria L ^a   Clark, Thomas A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b VERMONT DEPARTMENT OF HEALTH   (United States)

^c WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e MULTNOMAH COUNTY HEALTH DEPARTMENT   (United States)

^f MINNESOTA DEPARTMENT OF HEALTH   (United States)

^g NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^h Connecticut Department of Health ^*  (United States)

ⁱ Disease Control Divison   (United States)

^j NEW MEXICO DEPARTMENT OF HEALTH   (Argentina)

more..

Author keywords

acellular vaccine; Bordetella pertussis; mutations; pertactin; waning immunity

Indexed keywords

PERTACTIN; PERTUSSIS VACCINE; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; AGED; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; GENETICS; IMMUNE EVASION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PATHOLOGY; PERTUSSIS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; UNITED STATES; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL OUTER MEMBRANE PROTEINS; BLOTTING, WESTERN; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNE EVASION; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PERTUSSIS VACCINE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; UNITED STATES; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH; YOUNG ADULT;

EID: 84924937822     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu788     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Notice to readers: final 2012 reports of nationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep 2013; 62:669-82.
2. Centers for Disease Control and Prevention. Pertussis epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61: 517-22.
3. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126-32.
4. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52.
5. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012-9.
6. Bottero D, Gaillard ME, Basile LA, Fritz M, Hozbor DF. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America. J Appl Microbiol 2012; 112:1266-76.
7. Bouchez V, Caro V, Levillain E, Guigon G, Guiso N. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One 2008; 3:e2437.
8. Kallonen T, Grondahl-Yli-Hannuksela K, Elomaa A, et al. Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infect Genet Evol 2011; 11:2034-42.
9. Mooi FR, van Loo IH, van Gent M, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009; 15:1206-13.
10. Mooi FR, NA VDM, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation-two sides of the same coin. Epidemiol Infect 2014; 142:685-94.
11. Bouchez V, Brun D, Dore G, Njamkepo E, Guiso N. Bordetella paraper-tussis isolates not expressing pertactin circulating in France. Clin Micro-biol Infect 2011; 17:675-82.
12. Hegerle N, Paris AS, Brun D, et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of bordetellae not expressing pertactin. Clin Microbiol Infect 2012; 18:E340-6.
13. Otsuka N, Han HJ, Toyoizumi-Ajisaka H, et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One 2012; 7:e31985.
14. Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol 2012; 19:1703-4.
15. Bodilis H, Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis 2013; 19:471-4.
16. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 2013; 368:583-4.
17. Quinlan T, Musser KA, Currenti SA, Zansky SM, Halse TA. Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013. Mol Cell Probes 2014; 28:138-40.
18. Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol 2014; 21:119-25.
19. Mastrantonio P, Spigaglia P, van Oirschot H, et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 1999; 145(pt 8):2069-75.
20. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009; 27:6034-41.
21. Lam C, Octavia S, Ricafort L, et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis 2014; 20: 626-33.
22. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013; 368:581-2.
23. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454-6.
24. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 2014; 111: 787-92.
25. Hewlett EL, Burns DL, Cotter PA, et al. Pertussis pathogenesis-what we know and what we don't know. J Infect Dis 2014; 209:982-5.
26. Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 2007; 6:47-56.
27. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326-82.
28. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 2005; 65:1367-89.
29. Edwards KM, Decker MD, Plotkin S, Orenstein WA. Pertussis vaccine. In: Vaccines. 4th ed. Philadelphia, PA: Saunders Co, 2004:471-528.
30. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997; 16(4 suppl):S90-6.
31. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21:2003-14.
32. Inatsuka CS, Xu Q, Vujkovic-Cvijin I, et al. Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect Immun 2010; 78:2901-9.
33. Khelef N, Bachelet CM, Vargaftig BB, Guiso N. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect Immun 1994; 62:2893-900.
34. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131:e1716-22.